Fourth, the use of sodium glucose co-transporter 2 inhibitors (SGLT2-i) and glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy may reduce the risk of mortality and HF hospitalizations [42, 43]. This evidence concerns the gene GLP1R and hydrops fetalis.